What ScaleReady does

ScaleReady is a privately held joint venture, headquartered in New Brighton, Minnesota, formed in 2020 and commercially launched in January 2021 by Bio-Techne Corporation and Wilson Wolf Manufacturing (with Fresenius Kabi as an original founding partner) to commercialize scalable manufacturing technologies for the cell and gene therapy (CGT) industry. The company's flagship offering is the G-Rex closed-system bioreactor platform, built around proprietary gas-permeable membrane technology that delivers oxygen and nutrients on demand and enables linear scalability from research through commercial production in a single device family (6M, 10M, 100M, 500M formats). The portfolio has expanded to include ExCellerate animal-component-free media, GMP and RUO cytokines (including ProPak GMP-grade packaging), the TcBuster non-viral transposon-based gene delivery system, the SMART G-Rex sensor-enabled bioreactor line developed with Skroot Laboratories, and the G-Rex100M-CS AutoM robotic-compatible variant integrated with ABB Robotics and Cellular Origins automation.

ScaleReady's customers are cell and gene therapy developers across academic medical centers, biotechnology companies, and pharmaceutical firms working on CAR-T, TCR-T, TIL, NK, HSC, Treg and gamma-delta T cell therapies; G-Rex is reportedly used in approximately 50% of US clinical trial sponsors in this space and in six commercially approved drug products, including AMTAGVI (lifileucel). The business model combines hardware sales of G-Rex devices and the GatheRex liquid handling pump, recurring consumables revenue from media and cytokines sourced from Bio-Techne, and professional services around TcBuster gene editing. ScaleReady employs 11-50 people, operates in the United States, Canada, Europe, and Israel (with grant-supported engagement extending into India and Qatar), and uses a dedicated enterprise field sales team alongside the G-Rex Grant Program, which has awarded over $40 million in non-dilutive grants to drive platform adoption. Pricing is quote-based, contact-driven, and typically structured as multi-year contracts, with no publicly disclosed list pricing.

Name

ScaleReady

Legal name

ScaleReady LLC

Website

https://scaleready.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

ScaleReady is a Bio-Techne and Wilson Wolf joint venture that commercializes the G-Rex closed-system bioreactor platform and配套 consumables (media, cytokines, gene editing) for cell and gene therapy developers, serving academic medical centers, biotechs, and pharma working on CAR-T, TCR-T, TIL, NK, HSC and Treg therapies.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy Manufacturing Equipment

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Special Industry Machinery, Nec (3559), Measuring & Controlling Devices, Nec (3829)

akta.pro primary industry

Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers) (HLAGAIAG)

akta.pro secondary industry

Process Analytical Technology (PAT) & In-Line/At-Line Analytics (spectroscopy, sensors, monitoring) (HLAAAJAD)

Keywords

• Cell therapy manufacturing
• Bioreactor systems
• Gene therapy production
• CGT manufacturing platform
• Cell expansion technology

Headquarters

HQ city

Saint Paul

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. G-Rex Bioreactor Sales: ScaleReady generates revenue through direct sales of G-Rex closed-system bioreactors and related products including the GatheRex liquid handling pump. Products are sold to cell and gene therapy developers for research, clinical, and commercial manufacturing.
2. Reagents and Media: Sales of ExCellerate cell culture media and GMP cytokines sourced from Bio-Techne for immune cell expansion in CGT manufacturing processes.
3. TcBuster Gene Editing Services: Gene editing services using the TcBuster non-viral gene delivery platform, including proof-of-concept studies, process optimization, and technology licensing.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

ScaleReady is a joint venture that sells the G-Rex closed-system bioreactor platform — gas-permeable membrane devices used to manufacture cell and gene therapies (CAR-T, TCR-T, TIL, NK, HSC, Treg, gamma-delta T cells). The company offers the bioreactors in multiple sizes (6M to 500M-CS) with linear scalability, plus related cell culture media (ExCellerate), GMP cytokines (ProPak), the TcBuster non-viral gene delivery system, the SMART sensor-enabled bioreactors, and robotic handling variants.

Differentiator

Problem solved

Functional benefit

Products and services

• G-Rex Closed-System Bioreactor Platform Gas-permeable membrane closed-system bioreactors enabling linear scale-up of cell expansion from research to commercial CGT manufacturing without process changes. Used by approximately 50% of US clinical trial sponsors and is the manufacturing platform for six commercially approved drug products including AMTAGVI (lifileucel).
• G-Rex500M-CS Second Generation Updated version of the 500M-cell closed-system bioreactor with enhanced ergonomics and regulatory-aligned compliance documentation for CGT manufacturing.
• SMART G-Rex Sensor-Enabled Bioreactors Sensor-enabled G-Rex bioreactors with integrated SMART sensors that wirelessly transmit continuous metabolite data and harvest-readiness signals to an AWS-powered dashboard for remote monitoring and ERP/eQMS integration.
• G-Rex100M-CS AutoM Robotic Bioreactor Robotic-handling variant of the G-Rex100M-CS bioreactor featuring end-of-arm tooling compatibility for fully automated, sterile, closed-system cell therapy manufacturing workflows.
• ExCellerate Cell Culture Media Animal-component-free, serum-free, phenol-red-free cell culture media specifically formulated for immune cell expansion in G-Rex-based CGT manufacturing workflows.
• ProPak GMP Cytokines Animal-free, GMP-grade cytokines (IL-2, IL-7, IL-15, IL-21) packaged for single-step use in closed-system G-Rex manufacturing of CAR-T and TCR cell therapies, with low lot-to-lot variability and high bioactivity.
• TcBuster Non-Viral Gene Delivery System Transposon-based non-viral gene delivery platform that uses Red Flour Beetle transposase to insert CAR and TCR constructs, offering a safer insertion profile than viral vectors with high efficiency and scalability for cell therapy developers.
• GatheRex Liquid Handling Pump Liquid handling pump designed to support fluid management workflows in G-Rex-based cell therapy manufacturing processes.

Quantifiable outcome

• Can potentially treat 10,000 patients per year in 8x less space than conventional bioreactors
• +2 more outcomes

Named customers15 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability3 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered flagship and core.

• Bio-Techne CorporationflagshipStrategic or Co-development Partner · 21 January 2020Bio-Techne is a founding joint venture partner of ScaleReady. The partnership combines Bio-Techne's tools and technologies for cell culture, cell activation, and gene editing with Wilson Wolf's G-Rex bioreactor platform. Bio-Techne provides GMP cytokines, ExCellerate media, and TcBuster gene editing technology through ScaleReady.
• Wilson Wolf ManufacturingflagshipStrategic or Co-development Partner · 21 January 2020Wilson Wolf is a founding joint venture partner and the developer of G-Rex bioreactor technology. The company was founded in 1998 and has focused on cell and gene therapy manufacturing since 2010. Wilson Wolf manufactures G-Rex products under strong quality and manufacturing systems with no backorders and no major audit findings.
• Cellular OriginscoreTechnology or IntegrationPartnership to integrate ScaleReady's CGT manufacturing workflow with Cellular Origins' robotic technology. Initially focused on automation of the G-Rex platform for scalable, standardized cell therapy manufacturing.
• ABB RoboticscoreTechnology or IntegrationABB Robotics partners with ScaleReady for robotic automation of G-Rex devices. G-Rex bioreactors are designed for robotic handling with end-of-arm tooling compatible with ABB industrial robots for automated cell therapy manufacturing.
• Skroot LaboratoriescoreTechnology or IntegrationCollaboration with Skroot Laboratories to develop SMART (Single-use Metabolite Absorbing Resonant Transducer) sensors integrated into G-Rex platform for real-time, non-invasive cell growth monitoring.
• CTMCcoreTechnology or IntegrationPartnership to automate, close, and scale cell therapy manufacturing. CTMC uses ScaleReady's G-Rex platform in combination with Fresenius Kabi Lovo and Cue cell processing systems for high-throughput manufacturing.
• Fresenius KabiflagshipStrategic or Co-development PartnerFresenius Kabi was an original founding partner in the ScaleReady joint venture announced in January 2020. Provides cell processing systems (Lovo, Cue) that integrate with G-Rex platform for closed-system manufacturing.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Miltenyi Biotec: Miltenyi Biotec manufactures the CliniMACS Prodigy, an integrated cell processing and expansion platform that competes directly with G-Rex in CAR-T and other CGT manufacturing workflows. ScaleReady's own materials cite validated CliniMACS Prodigy + G-Rex integrations, confirming they serve overlapping customer workflows.
• Fresenius Kabi: Fresenius Kabi was an original ScaleReady founding partner and provides the Lovo and Cue cell processing systems that integrate with G-Rex in CTMC manufacturing workflows. They are both a partner and a comparable vendor offering adjacent/competing cell processing technologies in the CGT manufacturing ecosystem.
• Terumo BCT: Terumo BCT offers cell processing and cell expansion technologies (e.g., FINIA, Cell Expansion System) used in CGT manufacturing workflows. Their automated cell processing systems compete with G-Rex for clinical and commercial cell therapy manufacturing customers.

Broad incumbents

• Lonza Group: Lonza is a leading global CDMO with extensive CGT manufacturing capabilities, including bioreactor-based cell expansion services and proprietary processing platforms. Lonza competes with ScaleReady's technology by offering turnkey manufacturing services rather than equipment sales, but their Cocoon platform is a direct functional alternative for CGT developers.
• Sartorius AG: Sartorius supplies bioprocessing equipment including single-use bioreactors (e.g., BIOSTAT) used in cell therapy and biologics manufacturing. They compete with G-Rex at the upstream cell expansion step and have deeper relationships with large pharma commercial manufacturing operations.
• Cytiva (Danaher): Cytiva provides a broad portfolio of bioprocessing equipment, including Xuri cell expansion systems that compete with G-Rex for T-cell and other immune cell manufacturing. Cytiva's broader workflow coverage (upstream and downstream) makes them a comparable incumbent in CGT manufacturing tooling.
• Thermo Fisher Scientific: Thermo Fisher Scientific offers CGT manufacturing solutions including the Gibco CTS line of cell processing systems, incubators, and bioreactors. ScaleReady's own materials recommend Thermo Fisher Vios incubators as part of the G-Rex workflow, indicating direct ecosystem overlap and competitive positioning.

Emerging players

• MaxCyte: MaxCyte provides electroporation-based gene delivery technology for CGT manufacturing and has a partnership with ScaleReady through the G-Rex Grant Program. They compete with ScaleReady's TcBuster non-viral gene delivery system as an alternative approach to viral vectors in cell engineering workflows.
• PBS Biotech: PBS Biotech specializes in single-use, vertically scalable bioreactors for cell and gene therapy manufacturing, directly competing with G-Rex's scalable cell expansion technology. They focus on the same CGT manufacturing customer base with similar closed-system design principles.
• Cellares: Cellares is developing automated, high-throughput cell therapy manufacturing platforms (Cell Shuttle) that target the same CGT manufacturing bottleneck that ScaleReady's G-Rex plus robotic automation partnerships address. They represent an emerging fully-integrated automation alternative for large-scale CGT manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/wearescaleready

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments15 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ScaleReady